Sign in

    Julian Hung

    Healthcare Equity Research Analyst at Stifel Financial Corp.

    Julian Hung is a Healthcare Equity Research Analyst at Stifel Financial Corp., specializing in healthcare and biopharmaceutical sectors, with a focus on coverage of publicly traded pharmaceutical and biotechnology companies. He has covered numerous therapeutics and medical technology firms, leveraging his unique dual PharmD/MBA background to enhance his research insights and deliver actionable investment recommendations. Hung began his career as an equity research associate, advancing to his current role at Stifel, and brings a track record of strong sector-specific analysis though detailed performance metrics and rankings are not publicly available. He holds both a Doctor of Pharmacy (PharmD) and Master of Business Administration (MBA), underlining his professional credentials and specialized expertise in healthcare investment research.

    Julian Hung's questions to ACADIA PHARMACEUTICALS (ACAD) leadership

    Julian Hung's questions to ACADIA PHARMACEUTICALS (ACAD) leadership • Q4 2024

    Question

    Julian Hung, on for Paul Mattias, asked about the reasons for the wider-than-usual 2025 guidance range for NUPLAZID and questioned the company's confidence in securing favorable reimbursement for DAYBUE in the EU.

    Answer

    CFO Mark Schneyer attributed the wider NUPLAZID guidance to uncertainty surrounding the new Medicare Part D redesign, which could create both positive and negative volume impacts. CCO Tom Garner expressed high confidence in the EU launch of DAYBUE, citing strong inbound interest from caregivers, the build-out of an experienced team, and a growing body of real-world data to support reimbursement discussions.

    Ask Fintool Equity Research AI

    Julian Hung's questions to Quipt Home Medical (QIPT) leadership

    Julian Hung's questions to Quipt Home Medical (QIPT) leadership • Q1 2025

    Question

    Julian Hung asked about the historical level of bad debt expense, which is now embedded in revenue under U.S. GAAP, and whether the company's 8% to 10% organic growth target for 2025 remains achievable.

    Answer

    CFO Hardik Mehta stated that bad debt expense historically ran around 4-4.5% and was similar in Q1, but he expects this percentage to decline in the second half of calendar 2025 due to RCM team improvements. CEO Gregory Crawford reaffirmed that returning to the historical 8% to 10% organic growth rate is the team's active goal for the year.

    Ask Fintool Equity Research AI